Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($2.75) earnings per share for the quarter, FiscalAI reports.
Lakewood-Amedex Biotherapeutics Stock Down 2.6%
Shares of Lakewood-Amedex Biotherapeutics stock traded down $0.06 during trading hours on Friday, reaching $2.27. The company’s stock had a trading volume of 105,327 shares, compared to its average volume of 4,226,770. Lakewood-Amedex Biotherapeutics has a one year low of $1.66 and a one year high of $98.20. The stock has a market cap of $5.38 million and a P/E ratio of -1.14. The business has a fifty day simple moving average of $3.37.
Analyst Ratings Changes
Several analysts have recently commented on LABT shares. Wall Street Zen downgraded Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Weiss Ratings assumed coverage on Lakewood-Amedex Biotherapeutics in a report on Monday, July 20th. They issued a “sell (e-)” rating on the stock. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Lakewood-Amedex Biotherapeutics currently has an average rating of “Sell”.
About Lakewood-Amedex Biotherapeutics
We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.
Featured Stories
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
